VolitionRx initiated with a Buy at EF Hutton

EF Hutton analyst Constantine Davides initiated coverage of VolitionRx with a Buy rating and $6 price target. VolitionRx is an innovation leader in the field of epigenetics-based diagnostics, Davides tells investors in a research note. The analyst is bullish on the near-term opportunity to leverage the company’s "differentiated," nucleosome-based technology within animal health, as VolitionRx begins to "generate commercial traction from key commercial partnerships across 2023."